Literature DB >> 3385028

Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis.

E D Shelley1, W B Shelley.   

Abstract

Malignant pyoderma of the right ear developed in a 58-year-old woman, and it spread insidiously over the entire right side of the face. Pyoderma gangrenosum was diagnosed on the basis of clinical and histologic findings and the patient's history of ulcerative colitis and sclerosing cholangitis. After successive therapeutic failures with a score of conventional approaches over an 18-month period, oral cyclosporine, 10 mg/kg/day, was started. Significant healing of the skin was noted within 1 month. There was an associated remission of the patient's cholangitis and inflammatory bowel disease. The dosage of cyclosporine was progressively tapered and then discontinued after 7 months, when healing was complete. No relapse occurred in the subsequent 14 months, and there was an associated remission of the patient's cholangitis and inflammatory bowel disease. Cyclosporine merits serious attention for treatment of both pyoderma gangrenosum and sclerosing cholangitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3385028     DOI: 10.1016/s0190-9622(88)70111-5

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Pyoderma gangrenosum leading to bilateral involvement of ears.

Authors:  Marcia Carolline Dos Santos Sousa; Erica Freitas Lima Lemos; Orlando Oliveira De Morais; Anglya Samara Silva Leite Coutinho; Ciro Martins Gomes
Journal:  J Clin Aesthet Dermatol       Date:  2014-01

Review 2.  Recent advances in cyclosporine drug delivery: challenges and opportunities.

Authors:  Dhrumi Patel; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.

Authors:  W J Sandborn; R H Wiesner; W J Tremaine; N F Larusso
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

Review 5.  Ear Involvement in Inflammatory Bowel Disease: A Review of the Literature.

Authors:  Fotios S Fousekis; Maria Saridi; Eleni Albani; Fady Daniel; Konstantinos H Katsanos; Ioannis G Kastanioudakis; Dimitrios K Christodoulou
Journal:  J Clin Med Res       Date:  2018-06-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.